Edition:
United Kingdom

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

7,123JPY
13 Dec 2018
Change (% chg)

-- (--)
Prev Close
¥7,123
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,410,699
52-wk High
¥7,796
52-wk Low
¥5,200

Chart for

About

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company, mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The Company mainly provides its products and services in Japan, Europe and North America markets.

Overall

Beta: 0.99
Market Cap(Mil.): ¥2,061,380.00
Shares Outstanding(Mil.): 329.14
Dividend: 38.00
Yield (%): 1.15

Financials

  4507.T Industry Sector
P/E (TTM): 23.39 31.13 34.39
EPS (TTM): 267.76 -- --
ROI: 15.40 15.55 14.96
ROE: 17.05 16.92 16.52

Shionogi aims to double flu-drug market with FDA-approved treatment

TOKYO Japan's Shionogi & Co Ltd aims to double the global market for flu treatment with its drug Xofluza, the first flu drug approved by the U.S. Food and Drug Administration agency in nearly 20 years, its chief executive said.

29 Oct 2018

Shionogi aims to double flu-drug market with FDA-approved treatment

TOKYO, Oct 29 Japan's Shionogi & Co Ltd aims to double the global market for flu treatment with its drug Xofluza, the first flu drug approved by the U.S. Food and Drug Administration agency in nearly 20 years, its chief executive said.

29 Oct 2018

FDA approves first new flu drug in almost two decades

Japan's Shionogi & Co Ltd and Swiss drugmaker Roche won U.S. Food and Drug Administration (FDA) approval for their flu treatment, the first new flu drug approved by the agency in nearly 20 years.

24 Oct 2018

CORRECTED-FDA approves first new flu drug in almost two decades

Oct 24 Japan's Shionogi & Co Ltd and Swiss drugmaker Roche won U.S. Food and Drug Administration (FDA) approval for their flu treatment, the first new flu drug approved by the agency in nearly 20 years.

24 Oct 2018

FDA approves blood disorder drug made by Japan's Shionogi

The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi & Co Ltd's treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease.

31 Jul 2018

U.S. FDA approves blood disorder drug made by Japan's Shionogi

July 31 The U.S. Food and Drug Administration on Tuesday approved Japan-based Shionogi & Co Ltd's treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease.

31 Jul 2018

Earnings vs. Estimates